PharmaPoint: Osteoporosis - Current and Future Players

NEW YORK, May 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - Current and Future Players
http://www.reportlinker.com/p01171138/PharmaPoint-Osteoporosis---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Osteoporosis - Current and Future Players

Summary

Osteoporosis is caused by the gradual weakening of the bones due to abnormal osteocyte function, which occurs as a result of hormonal fluctuations, vitamin deficiency, or aging, and leads to reduced mobility and/or bone fractures.

GlobalData has released its pharma report, "PharmaPoint: Osteoporosis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Osteoporosis Market. The report identifies and analyses the key companies shaping and driving the global Osteoporosis market. The report provides insight into the competitive Osteoporosis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).

Scope

- Investigation of current and future market competition for Osteoporosis.
- Competitor assessment.
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL)

Reasons to buy

- Gain a high level view of the trends shaping and driving the Osteoporosis market.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
3 Market Outlook 10
3.1 Global Markets 10
3.1.1 Forecast 10
3.1.2 Drivers and Barriers – Global Issues 13
4 Current and Future Players 15
4.1 Overview 15
4.2 Trends in Corporate Strategy 16
4.3 Company Profiles 17
4.3.1 Amgen 17
4.3.2 Merck 19
4.3.3 Eli Lilly 22
4.3.4 Pfizer 25
4.3.5 Radius Health 27
5 Appendix 30
5.1 Bibliography 30
5.2 Abbreviations 31
5.3 Methodology 32
5.4 Forecasting Methodology 32
5.4.1 Diagnosed Osteoporosis Patients 32
5.4.2 Percent Drug-Treated Patients 32
5.4.3 Drugs Included in Each Therapeutic Class 33
5.4.4 Launch and Patent Expiry Dates 33
5.4.5 General Pricing Assumptions 34
5.4.6 Individual Drug Assumptions 34
5.4.7 Generic Erosion 38
5.4.8 Pricing of Pipeline Agents 39
5.5 Physicians and Specialists Included in this Study 40
5.5.1 About the Authors 41
5.5.2 Global Head of Healthcare 42
5.6 About GlobalData 43
5.7 Contact Us 43
5.8 Disclaimer 43

List of Tables

Table 1: Global Sales Forecasts ($m) for Osteoporosis, 2012-2022 11
Table 2: Osteoporosis Market – Drivers and Barriers, 2012–2022 13
Table 3: Key Companies in the Osteoporosis Market, 2012 15
Table 4: Amgen's Osteoporosis Therapy Portfolio Assessment, 2012 18
Table 5: Amgen SWOT Analysis, 2012 18
Table 6: Merck's Osteoporosis Therapy Portfolio Assessment, 2012 20
Table 7: Merck SWOT Analysis, 2012 21
Table 8: Eli Lilly's Osteoporosis Therapy Portfolio Assessment, 2012 23
Table 9: Eli Lilly SWOT Analysis, 2012 23
Table 10: Pfizer's Osteoporosis Therapy Portfolio Assessment, 2012 25
Table 11: Pfizer SWOT Analysis, 2012 26
Table 12: Radius Health's Osteoporosis Therapy Portfolio Assessment, 2012 28
Table 13: Radius Health SWOT Analysis, 2012 28
Table 14: Key Launch Dates 33
Table 15: Key Patent Expiries 33
Table 16: Number of High-Prescribing Physicians Surveyed 40

List of Figures

Figure 1: Global Sales for Osteoporosis by Region, 2012–2022 12
Figure 2: Company Portfolio Gap Analysis in Osteoporosis, 2012–2022 16

To order this report:
Pathology Industry: PharmaPoint: Osteoporosis - Current and Future Players

__________________________

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker